BCR-ABL1 transcript doubling time as a predictor for treatment-free remission failure after imatinib discontinuation in chronic myeloid leukaemia in chronic phase

The doubling time (DT) of the BCR-ABL1 quantitative polymerase chain reaction (qPCR) transcript level reflects the re-growing fraction of leukaemic cells after discontinuation of tyrosine kinase inhibitor (TKI). The present study analyzed monthly DT within six months after imatinib discontinuation in 131 patients. Monthly DT was calculated as x = ln(2)/K, where x is the DT and K is the fold BCR-ABL1 change from the previous value divided by the number of days between each measurement. The optimal DT value was determined as 12 center dot 75 days at two months using a recursive partitioning method. The patients were stratified into three groups: the high-risk group (DT0, with rapidly proliferating chronic myeloid leukaemia (CML) cells; n = 26) showed the lowest molecular relapse-free survival (mRFS) of 7 center dot 7% at 12 months, compared to 53 center dot 6% in the intermediate-risk group (DT >= 12 center dot 75 days, with slowly proliferating CML cells; n = 16) or 90 center dot 0% in the low-risk group (DT <= 0, i.e., without proliferating CML cells; n = 71; P < 0 center dot 001). Monthly assessment of DT helps identify high-risk patients for treatment-free remission failure with an imminent risk of molecular recurrence, and to define low-risk patients who can be spared the frequent monitoring of monthly molecular tests.

Automated summary

The study found that monthly assessment of doubling time can help identify the risk of molecular recurrence in patients with chronic myeloid leukemia after discontinuation of imatinib, thereby distinguishing between high-risk and low-risk patients.